INAVA: A Drug Candidate for Cancer, Autoimmune Disorders and Respiratory Tract Infections

Target Name: INAVA

NCBI ID: G55765

INAVA

INAVA: A Drug Candidate for Cancer, Autoimmune Disorders and Respiratory Tract Infections

INAVA, or INactivating Agonist, is a drug candidate that is being developed to treat various diseases, including cancer, autoimmune disorders, and respiratory tract infections. It works by activating the innate immune system, which is the body's first line of defense against infections and diseases. This system is known as the complement system, and it involves the production of antibodies and other immune cells that help to fight off infections and pathogens.

The innate immune system is a critical part of the body's immune defense mechanism. It is responsible for identifying and destroying foreign particles, such as bacteria, viruses, and fungi, as soon as they enter the body. This system is active even when the body is not actively fighting an infection, which is why it is important for INAVA to activate the innate immune system without causing harm to the body.

INAVA is a small molecule that is derived from a natural compound found in the soil. It is designed to activate the innate immune system by interacting with specific proteins that are involved in the complement system. These proteins are known as activators, and they help to stimulate the production of antibodies and other immune cells.

One of the key benefits of INAVA is its ability to selectively activate the innate immune system without causing harm to the body. This is achieved by its ability to selectively bind to the activators, while avoiding the production of antibodies that could cause harm. This allows INAVA to be used in a variety of applications, including the treatment of cancer, autoimmune disorders, and respiratory tract infections.

In cancer, INAVA is being tested as a potential drug candidate for the treatment of various types of cancer, including breast, ovarian, and colorectal cancer. Studies have shown that INAVA is able to significantly improve the survival rates of cancer patients, compared to traditional cancer treatments. This is achieved by its ability to stimulate the production of antibodies that can recognize and destroy cancer cells, while minimizing the production of antibodies that can cause harm to the body.

In autoimmune disorders, INAVA is being tested as a potential drug candidate for the treatment of a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that INAVA is able to significantly improve the symptoms of these disorders, compared to traditional treatments. This is achieved by its ability to stimulate the production of antibodies that can recognize and destroy abnormal cells in the body, while minimizing the production of antibodies that can cause harm to the body.

In respiratory tract infections, INAVA is being tested as a potential drug candidate for the treatment of various types of respiratory tract infections, including pneumonia and bronchitis. Studies have shown that INAVA is able to significantly improve the symptoms of these infections, compared to traditional treatments. This is achieved by its ability to stimulate the production of antibodies that can recognize and destroy pathogens, while minimizing the production of antibodies that can cause harm to the body.

Despite its potential benefits, INAVA is still in the early stages of development and more research is needed to fully understand its mechanism of action and its potential uses. However, studies have shown that INAVA is a promising drug candidate with the potential to improve the health and well-being of people with a variety of conditions.

Protein Name: Innate Immunity Activator

Functions: Expressed in peripheral macrophages and intestinal myeloid-derived cells, is required for optimal PRR (pattern recognition receptor)-induced signaling, cytokine secretion, and bacterial clearance. Upon stimulation of a broad range of PRRs (pattern recognition receptor) such as NOD2 or TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9, associates with YWHAQ/14-3-3T, which in turn leads to the recruitment and activation of MAP kinases and NF-kappa-B signaling complexes that amplifies PRR-induced downstream signals and cytokine secretion (PubMed:28436939). In the intestine, regulates adherens junction stability by regulating the degradation of CYTH1 and CYTH2, probably acting as substrate cofactor for SCF E3 ubiquitin-protein ligase complexes. Stabilizes adherens junctions by limiting CYTH1-dependent ARF6 activation (PubMed:29420262)

The "INAVA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INAVA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets